ELV vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Elevance Health presents a complex value proposition characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock is objectively undervalued, trading below its Graham Number ($340.31) and significantly below its intrinsic value ($763.75), recent financial performance is concerning with a -44.8% Q/Q EPS decline. The combination of bearish technicals and insider selling offsets the attractive valuation and strong analyst buy ratings. Consequently, the stock appears to be in a transition phase where deep value meets fundamental weakness.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ELV vs MRK: Head-to-Head Comparison
This page compares Elevance Health, Inc. (ELV) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.